These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32236684)

  • 21. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonate use and subsequent hip fracture in South Korea.
    Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
    Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review.
    Zhao S; Zhao W; Du D; Zhang C; Zhao T; Zheng L; Jin L; Gu M; Xu J; Yang Z
    J Investig Med; 2022 Mar; 70(3):837-843. PubMed ID: 34893517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use.
    Prieto-Alhambra D; Javaid MK; Judge A; Maskell J; Kiran A; de Vries F; Cooper C; Arden NK
    Arthritis Rheum; 2011 Apr; 63(4):992-1001. PubMed ID: 21452321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.
    Bondo L; Eiken P; Abrahamsen B
    Osteoporos Int; 2013 Jan; 24(1):245-52. PubMed ID: 22638712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
    Wu J; Zhang Q; Yan G; Jin X
    J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
    JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study.
    Arias LH; Treceño C; García-Ortega P; Rodríguez-Paredes J; Escudero A; Sáinz M; Salado I; Velasco V; Carvajal A
    Eur J Clin Pharmacol; 2013 Mar; 69(3):559-64. PubMed ID: 22821192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
    Iwamoto J; Matsumoto H; Takeda T
    Curr Med Res Opin; 2008 May; 24(5):1379-84. PubMed ID: 18384711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral bisphosphonates are associated with reduced mortality after hip fracture.
    Beaupre LA; Morrish DW; Hanley DA; Maksymowych WP; Bell NR; Juby AG; Majumdar SR
    Osteoporos Int; 2011 Mar; 22(3):983-91. PubMed ID: 21052642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of second hip fracture and compliant use of bisphosphonate.
    Lee YK; Ha YC; Yoon BH; Koo KH
    Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates and mortality: confounding in observational studies?
    Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
    Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Lyu H; Jundi B; Xu C; Tedeschi SK; Yoshida K; Zhao S; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 May; 104(5):1753-1765. PubMed ID: 30535289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fracture mortality: associations with epidemiology and osteoporosis treatment.
    Sattui SE; Saag KG
    Nat Rev Endocrinol; 2014 Oct; 10(10):592-602. PubMed ID: 25091729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can Bisphosphonates Prevent Recurrent Fragility Fractures? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Lee SY; Jung SH; Lee SU; Ha YC; Lim JY
    J Am Med Dir Assoc; 2018 May; 19(5):384-390.e1. PubMed ID: 29704927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
    Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
    Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.